Today, a Director at Vanda (NASDAQ: VNDA), Thomas Watkins, bought shares of VNDA for $74.7K.
This recent transaction increases Thomas Watkins’ holding in the company by 300% to a total of $313K.
See today’s analyst top recommended stocks >>
Based on Vanda’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $43.59 million and quarterly net profit of $3.07 million. In comparison, last year the company earned revenue of $37.42 million and had a GAAP net loss of $7.65 million. The company has a one-year high of $20.40 and a one-year low of $11.90. Currently, Vanda has an average volume of 1.44M.
Starting in May 2013, VNDA received 92 Buy ratings in a row. Eight different firms, including Evercore ISI and Jefferies, currently also have a Buy rating on the stock.
The insider sentiment on Vanda has been negative according to 21 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.
